BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Staccato loxapine regulatory update

Alexza plans to resubmit an NDA for Staccato loxapine (AZ-004) to treat agitation in patients with schizophrenia or bipolar disorder on Aug. 8 instead of in July as previously planned. The resubmission will include data from a human factors study, stability data from production batches, a...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >